Novo Nordisk has successfully launched a drug for treating obesity. But due to bottlenecks in the supply chain, US demand cannot be met. Analysts withdraw their buy recommendation.
The share of the Danish pharmaceutical company Novo Nordisk is on a downward slide. On Monday, the Novo Nordisk share temporarily lost around 16 percent.
The reason for the crash: Novo Nordisk says it cannot meet US demand for liraglutide, a weight-loss drug. The reason is problems with a supplier.
Now, analysts at Citigroup are warning that this could hurt 2022 operating profit by a high single-digit percentage. In addition to Citigroup analysts, analysts from JPMorgan and Deutsche Bank also withdrew their buy recommendation for Novo Nordisk shares.
According to Novo Nordisk, the drug liraglutide has an antidiabetic effect, increases the insulin sensitivity of body cells, delays gastric emptying and sends more satiety messages to the brain.
Author: Ferdinand Hammer, wallstreet:online central editorial office
Values included: DK0060534915
How to get the perfect look for Cos...
Test winner at Stiftung Warentest:...
Cream for Rosacea: The Best Creams
Dry elbows: This is how brittle ski...